Skip to main content

3D Genomic Maps

Cancer's Progress Detailed by 3D Genomic Maps


Researchers have long known that cancer alters its genome as it evolves. What has been less clear is how, when, and why genomic structures change as cancer progresses. A new Yale study published Aug. 18 in Nature Genetics reveals critical insights and potential biomarkers of stage-specific cancer development.

Using a technique called chromatin tracing, Yale researchers created detailed 3D maps of genome structures in individual cells in mouse models of lung and pancreatic cancers, driven by the cancer-causing gene KRAS. The maps reveal how chromosomes fold and genes are positioned in the cell nucleus. They also chart cancer’s route from pre-cancerous to advanced disease, even identifying different cancer cell states based solely on the 3D structure of their genomes.

“Importantly, using the unprecedented 3D genome maps, we developed new ways to better nominate cancer-driving genes. These are potential new drug targets for lung cancer, the top cause of cancer death worldwide,” says co-senior author Siyuan (Steven) Wang, PhD, associate professor of genetics and cell biology at Yale School of Medicine (YSM).

“On the basic genome biology side, we also discovered a completely new function for how the 3D genome is compartmentalized to enable single cancer cells to progress to more advanced states,” he says, Co-senior author Mandar Deepak Muzumdar, MD, associate professor of genetics and of internal medicine (oncology) at YSM says: “Although cancers are thought to be quite heterogeneous, what is remarkable is that the global 3D structure of the genome evolves similarly in cancer cells within and across tumors in these models.

“By focusing specifically on these convergent, stereotypical changes, how they are regulated, and how they impact gene expression, we identified novel genes that delineate cancer prognosis and are crucial for cancer cells to grow,” says Muzumdar, who is a member of Yale Cancer Biology Institute and Yale Cancer Center. The study suggests that the detailed data resulting from this method and its broad application could improve future cancer diagnostics and staging, as well as help identify new therapy targets by understanding what cancerous cells need to survive and thrive.

The study was led by Yale’s Department of Genetics at YSM, including co-first authors Miao Liu, PhD; Shengyan Jin, PhD; and Sherry S. Agabiti, PhD. Other contributors included numerous YSM departments, Yale Cancer Biology Institute, Yale Center for RNA Science and Medicine, Yale Liver Center, and Yale Computational Biology and Biomedical Informatics.

Using the advanced cancer 3D genome mapping methodologies established in this work, the researchers are next investigating additional subtypes of lung and pancreatic cancers and directly studying human patient samples, in collaboration with other investigators at the Yale Cancer Center. “These 3D genome maps are just the tip of the iceberg,” say Drs. Muzumdar and Wang. “We are just getting started in using this new type of single-cell biologic information to uncover cancer’s untold secrets, aiming to improve treatment and clinical outcomes in the long-term.”

genome sequencing, genome editing, human genome, comparative genomics, genome mapping, structural genomics, functional genomics, microbial genomics, plant genomics, animal genomics, genome variation, genome-wide association studies, mitochondrial genome, epigenomics, genome annotation, metagenomics, genome informatics, personalized genomics, genome evolution

#GenomeSequencing, #GenomeEditing, #HumanGenome, #ComparativeGenomics, #GenomeMapping, #StructuralGenomics, #FunctionalGenomics, #MicrobialGenomics, #PlantGenomics, #AnimalGenomics, #GenomeVariation, #GWAS, #MitochondrialGenome, #Epigenomics, #GenomeAnnotation, #Metagenomics, #GenomeInformatics, #PersonalizedGenomics, #GenomeEvolution, #SyntheticGenomics

International Conference on Genetics and Genomics of Diseases

Visit: genetics-conferences.healthcarek.com

Award Nomination: genetics-conferences.healthcarek.com/award-nomination/?ecategory=Awards&rcategory=Awardee

Award registration: genetics-conferences.healthcarek.com/award-registration/

For Enquiries: support@healthcarek.com

Get Connected Here
---------------------------------
---------------------------------
in.pinterest.com/Dorita0211
twitter.com/Dorita_02_11_
facebook.com/profile.php?id=61555903296992
instagram.com/p/C4ukfcOsK36
genetics-awards.blogspot.com/
youtube.com/@GeneticsHealthcare
linkedin.com/in/genetics-research-160337363/

Comments

Post a Comment

Popular posts from this blog

Fruitful innovation

Fruitful innovation: Transforming watermelon genetics with advanced base editors The development of new adenine base editors (ABE) and adenine-to-thymine/ guanine base editors (AKBE) is transforming watermelon genetic engineering. These innovative tools enable precise A:T-to-G and A:T-to-T base substitutions, allowing for targeted genetic modifications. The research highlights the efficiency of these editors in generating specific mutations, such as a flowerless phenotype in ClFT (Y84H) mutant plants. This advancement not only enhances the understanding of gene function but also significantly improves molecular breeding, paving the way for more efficient watermelon crop improvement. Traditional breeding methods for watermelon often face challenges in achieving desired genetic traits efficiently and accurately. While CRISPR/Cas9 has provided a powerful tool for genome editing, its precision and scope are sometimes limited. These limitations highlight the need for more advanced gene-e...
Post a Comment
Read more

Genetic factors with clinical trial stoppage

Genetic factors associated with reasons for clinical trial stoppage Many drug discovery projects are started but few progress fully through clinical trials to approval. Previous work has shown that human genetics support for the therapeutic hypothesis increases the chance of trial progression. Here, we applied natural language processing to classify the free-text reasons for 28,561 clinical trials that stopped before their endpoints were met. We then evaluated these classes in light of the underlying evidence for the therapeutic hypothesis and target properties. We found that trials are more likely to stop because of a lack of efficacy in the absence of strong genetic evidence from human populations or genetically modified animal models. Furthermore, certain trials are more likely to stop for safety reasons if the drug target gene is highly constrained in human populations and if the gene is broadly expressed across tissues. These results support the growing use of human genetics to ...
Post a Comment
Read more

Genetics study on COVID-19

Large genetic study on severe COVID-19 Bonn researchers confirm three other genes for increased risk in addition to the known TLR7 gene Whether or not a person becomes seriously ill with COVID-19 depends, among other things, on genetic factors. With this in mind, researchers from the University Hospital Bonn (UKB) and the University of Bonn, in cooperation with other research teams from Germany, the Netherlands, Spain and Italy, investigated a particularly large group of affected individuals. They confirmed the central and already known role of the TLR7 gene in severe courses of the disease in men, but were also able to find evidence for a contribution of the gene in women. In addition, they were able to show that genetic changes in three other genes of the innate immune system contribute to severe COVID-19. The results have now been published in the journal " Human Genetics and Genomics Advances ". Even though the number of severe cases following infection with the SARS-CoV-...
Post a Comment
Read more